Hi Nick,
It must be very difficult for you given the little information your dad gives you about his current situation. You might ask your dad if you can go with him to his appointment on Wednesday as him keeping you in the dark is making things worse for you, although I am sure he is only trying to protect you.
Given that your dad is on the Spirit 2 trial, he will be monitored very closely. It could be that his doctors might need to change therapy or dose and therefore he will need to either change trial arms or come off the trial altogether- but I am only guessing as you have so little information about your dads real position.
I am sure his doctors will offer an alternative- it might be that his disease might be better controlled by one of the other drugs available i.e nilotinib, or depending on the marrow test results ponatinib (this is a 3rd generation drug that is currently in clinical trial)
I imagine that your dad is trying hard to protect you, but you might try to explain to him that knowledge is the best option for surviving CML.... Fear is our worst enemy and lack of information only serves to make that enemy more powerful.
I do hope you can persuade your dad that you can help him understand what it happening... and that by allowing you to become involved more closely he will be helping you cope.
Do try not to worry about the present situation re: NICE and access to dasatinib and nilotinib. If your dad is being treated at a specialist centre- and I assume he is as he is on a clinical trial- then he has the best options available to continue to access the best therapy.
Given his brothers both had acute leukaemia (?)he must be very scared, but CML is not the same disease as AML or ALL, and its mechanisms are very well understood which is why there are at least 4 targeted therapies available (2 -bosutinib and ponatinib- available through clinical trials).
I hope this has been of some help to you. I have copied the Spirit2 website below with the trial protocol.... is your dad being treated on the 400mg imatinib arm or the 100mg dasatinib arm?
Sandy
http://www.spirit-cml.org/spirit-2-home/about.aspx
SPIRIT 2 is a Phase III, multicentre, open-label, prospective randomised trial comparing imatinib 400 mg daily versus dasatinib 100 mg daily in patients with newly-diagnosed chronic phase Chronic Myeloid Leukaemia (CML).
The study opened in August 2008 and it is expected that 810 patients will be entered into the study over the next 3-4 years.
Patients will be randomised in equal proportions to one of the following treatment groups:
a) Imatinib 400 mg daily
b) Dasatinib 100 mg daily
The primary endpoint is to compare Event Free Survival (EFS) between the two arms at 5 years.
Patients must be newly diagnosed (<3 months) and have been treated with only hydroxycarbamide (hydroxyurea) and/or anagrelide.